Filing Details
- Accession Number:
- 0001127602-11-006412
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2011-02-18 17:22:14
- Reporting Period:
- 2011-02-17
- Filing Date:
- 2011-02-18
- Accepted Time:
- 2011-02-18 17:22:14
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 850693 | Allergan Inc | AGN | Pharmaceutical Preparations (2834) | 951622442 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1158587 | R Michael Gallagher | 2525 Dupont Drive Irvine CA 92612 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2011-02-17 | 5,000 | $36.85 | 70,200 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2011-02-17 | 5,000 | $75.54 | 65,200 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Nonemployee Director Stock Option (Right to Buy) | Disposition | 2011-02-17 | 5,000 | $0.00 | 5,000 | $36.85 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2004-04-25 | 2013-04-24 | No | 4 | M | Direct |
Footnotes
- The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $75.51 to $75.605, inclusive. The reporting person undertakes to provide Allergan, Inc., any security holder of Allergan, Inc., or the staff of the Securities and Exchange Commission, upon request, the full information regarding the number of shares sold at each price within the range set forth in this footnote.
Billionaire Hedge Funds
